Home › Borstkanker › Indiana › Indianapolis
Borstkanker klinische studies in Indianapolis, IN
20 studies voor Borstkanker zoeken deelnemers op locaties in en rond Indianapolis (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
RekruterenFase 3
- Community Health Network, Inc, Indianapolis
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
RekruterenFase 3
- Investigative Clinical R of Indiana, Indianapolis
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
RekruterenFase 2Gezonde vrijwilligers welkom
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RekruterenFase 1
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RekruterenFase 1/2
- Community Health Network, Indianapolis
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RekruterenFase 3
- Franciscan Health ( Site 0077), Indianapolis
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Rekruteren
- Indiana University, Indianapolis
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RekruterenFase 1
- Indiana University (IU) School of Medicine, Indianapolis
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RekruterenFase 3
- Indiana University Health University Hospital, Indianapolis
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
RekruterenFase 2
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
RekruterenFase 2
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
RekruterenFase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
- Community Cancer Center East, Indianapolis
- en nog 5
HER2 Vaccine for Locally Advanced Breast Cancer
RekruterenFase 1
- Indiana University Melvin & Bren Simon Comprehensive Cancer Center, Indianapolis
Exercise in Metastatic Breast Cancer: EMBody
Rekruteren
- Indiana University Melvin & Bren Simon Cancer Center, Indianapolis
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
RekruterenFase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Franciscan Health Indianapolis, Indianapolis
- Franciscan Health Mooresville, Mooresville · 16 mijl verwijderd
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
RekruterenFase 2
- Indiana University, Indianapolis
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
RekruterenFase 1/2
- Research Site, Indianapolis
NearWave Optical Molecular Monitoring
Rekruteren
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
RekruterenFase 3
- Franciscan Health Indianapolis, Indianapolis
- Franciscan Health Mooresville, Mooresville · 16 mijl verwijderd
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
RekruterenFase 1
- Community Health Network, Indianapolis
Borstkanker studies in andere steden
- New York City, NY136 studies
- Houston, TX126 studies
- Boston, MA112 studies
- Nashville, TN81 studies
- Los Angeles, CA73 studies
- Edison, NJ68 studies
- St. Louis, MO64 studies
- Queens, NY64 studies
- Durham, NC64 studies
- Chicago, IL59 studies
- Philadelphia, PA56 studies
- Dallas, TX55 studies
Andere studies in Indianapolis
- Niet-kleincellige longkanker32 studies
- Kanker (alle vormen)24 studies
- Hartfalen23 studies
- Obesitas20 studies
- Metastatische kanker19 studies
- Colorectale kanker18 studies
- Eierstokkanker17 studies
- Cardiovasculaire ziekte17 studies
- Longkanker16 studies
- Type 1-diabetes14 studies
- Endometriumkanker14 studies
- Ziekte van Alzheimer14 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.